Eli Lilly to Pull Cancer Drug From Market After Failed Study

Eli Lilly & Co. said Thursday it plans to withdraw its cancer drug Lartruvo from the market after a study showed that it failed to prolong overall survival in a clinical trial.

The company will establish an access program to allow some patients with soft-tissue sarcoma—a cancer that develops in connective tissue including muscle—to continue taking the drug with limited interruption after it’s withdrawn from the market. Lilly didn’t provide a specific timeline and said it’s working with health regulators on its plans.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Stock market fails to extend climb to records as energy-sector retreat weighsThe S&P 500 and the Nasdaq Composite indexes on Wednesday failed to extend their climb into record territory as a pullback in the mostly buoyant energy...
Herkunft: MarketWatch - 🏆 3. / 97 Weiterlesen »